Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Employees - 256, CEO - Dr. Vladimir Coric M.D., Sector - Healthcare, Country - US, Market Cap - 2.10B

Altman ZScore(max is 10): -0.29, Piotroski Score(max is 10): 1, Working Capital: $384246000, Total Assets: $615107000, Retained Earnings: $-1345714000, EBIT: -884606000, Total Liabilities: $191671000, Revenue: $0

AryaFin Target Price - $0.72 - Current Price $20.55 - Analyst Target Price $62.20